Ex. 2001 - 020 File History [EXCERPT] | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2002 - 824 File History [EXCERPT] | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2003 - U.S. Pat Appl Publ US2021-0277104A1 (824 Patent) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2005 Proposed Protective Order (-00258) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2006 Proposed Protective Order Redline (-00258) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2012 - J&J Press Release (3.21.2025) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2013 - J&J Press Release (1.8.2026) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2014 - Simponi Aria Prescribing Information (April 2025) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2015 - Bio-Thera Solutions, Ltd. 2019 Annual Report (Chinese) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2016 - Bio-Thera 2019 Annual Report (Ex.2015) English Translation Excerpt & Certificate | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2017 - Bio-Thera Solutions, Ltd. 2020 Annual Report (Chinese) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2018 - Bio-Thera 2020 Annual Report (Ex.2017) English Translation Excerpt Certificate | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2019 - Bio-Thera Solutions, Ltd. 2021 Annual Report (Chinese) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2020 - Bio-Thera 2021 Annual Report (Ex.2019) English Translation Excerpt & Certificate | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2021 - Bio-Thera Solutions, Ltd. 2024 Annual Report (Chinese) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2022 - Bio-Thera 2024 Annual Report (Ex.2021) English Translation Excerpt & Certificate | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2023 - Bio-Thera Solutions, Ltd. 2025 Semi-Annual Report (Chinese) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2024 - Bio-Thera 2025 Semi-Annual Report (Ex. 2023) English Translation Excerpt & Certificate | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2026 - Intas Pharms Entity Data (4.2.2026) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2027 - Intas Pharms, Private Company Profile (updated 3.16.2026) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2028 - Bio-Thera Solutions Company News (3.23.2026) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2031 - 2021 Rpt to Congress, U.S.-China Econ & Sec Review Comm'n [EXCERPT] | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2033 - USPTO-PTAB Mem, Enforcement & Non-Waiver of 37 C.F.R. 42.104(B)(4) (7.31.2025) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2034 - USPTO-PTAB Mem, Add'l Discretionary Institution Considerations (3.11.2026) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2036 - Bas (2025) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2037 - Beauroyre (Abacum) (6.25.2025) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2038 - Cohen (2014) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2040 - Nonaka (2018) [EXCERPT] | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2043 - Qichacha (QCC), Bio-Thera Solutions, Ltd. Enterprise Credit Report (4.8.2026) (Chinese) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2044 - QCC Report (Ex. 2043) English Translation Excerpt & Certificate | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2045 - Qichacha (QCC), Bio-Thera w-Guangzhou Zhongke Yuechuang No. 3 Venture Cap P'ship (Chinese) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2046 - QCC Report (Ex. 2045) English Translation & Certificate | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2047 - North Carolina Governor Press Release (1.9.2026) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2049 - ClinicalTrials.gov History of Changes Study NCT02181673 | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2050 - Accord BioPharma Press Release (5.18.2026) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2051 - USPTO-PTAB Mem, Corning v PPC Broadband Precedential designation (Paper 68) (10.28.2025) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2500_REDACTED_Declaration of A. Donlon (-00258) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2501_REDACTED_Declaration of Luke Brennan (-00258) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2502_REDACTED_Declaration of Thao Marzullo (-00258) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Patent Owner Janssen Biotech, Inc.'s Motion to File Documents Under Seal and for a Protective Order | May 27, 2026 | PAPER | PATENT OWNER |
Ex. 2500_HC-AEO_Declaration of A. Donlon (-00258) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2501_HC-AEO_Declaration of Luke Brennan (-00258) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Ex. 2502_HC-AEO Declaration of Thao Marzullo (-00258) | May 27, 2026 | EXHIBIT | PATENT OWNER |
Patent Owner's Brief on Discretionary Denial | May 27, 2026 | PAPER | PATENT OWNER |
Patent Owner's Brief on Discretionary Denial | May 27, 2026 | PAPER | PATENT OWNER |
Patent Owner's Mandatory Notices | Apr 10, 2026 | PAPER | PATENT OWNER |
Patent Owner's Power of Attorney | Apr 10, 2026 | PAPER | PATENT OWNER |
Notice filing date accorded | Mar 27, 2026 | PAPER | BOARD |
EX1001 - U.S. Patent No. 11,041,020 to Harrison et al. (June 22, 2021) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1002 - U.S. Patent No. 11,014,982 to Harrison et al. (May 25, 2021) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1003 - U.S. Patent No. 12,122,824 to Harrison et al. (Oct. 22, 2024) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1004 - U.S. Patent No. 12,291,566 to Harrison et al. (May 6, 2025) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1007 - Excerpts from prosecution history of U.S. Appl'n No. 16/517,594 | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1008 - Excerpts from prosecution history of U.S. Appl'n No. 16/517,592 | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1009 - Excerpts from prosecution history of U.S. Appl'n No. 17/320,490 | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1010 - Excerpts from prosecution history of U.S. Appl'n No. 17/237,650 | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1011 - ClinicalTrials.gov, NCT02181673 (Version 23) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1012 - M. E. Weinblatt, et al., Intravenous golimumab is effective | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1013 -M. Rossini, et al., Why golimumab in the treatment | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1014 - ClinicalTrials.gov, NCT02186873 (Version 24) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1015 - SIMPONI (golimumab) injection, for subcutaneous use, FOOD AND DRUG | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1016 - R. D. Inman, et al., Efficacy and Safety of Golimumab | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1017 - Six Sigma | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1018 - BLA Approved re BLA 125289, FOOD AND DRUG ADMIN. (Apr. 24, 2009) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1019 - BLA Approved re BLA 125433, FOOD AND DRUG ADMIN. (July 18, 2013) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1022 - S. D’Angelo, Psoriatic arthritis: treatment strategies | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1024 - U.S. Patent Publication 2009/0123378 to Wong et al. | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1025 - International Publication WO 2008/063213 A2 to Medich et al. | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1026 - J. Kay & M. U. Rahman, Golimumab (Kay 2009) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1027 - E. C. Keystone & C. F. Ware, Tumor Necrosis | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1028 - H. Shim, One target, different effects (Shim 2011) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1029 - J. Kalden, Anti-TNF therapy: what have we learned in 12 years? | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1030 - L. C. Coates, et al., Anti-TNF therapy in ankylosing spondylitis | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1032 - SIMPONI ARIA (golimumab) injection, for intravenous use | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1033 - D. van der Heijde, et al., The Effect of Golimumab Therapy | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1034 - Administrative and Correspondence Documents, 125433Orig1s000 | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1035 - M. K. Doyle et al., Effects of subcutaneous and intravenous | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1036 - U.S. Publication No. 2008/0311043 to Hoffman et al. (“Hoffman”) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1037 - U.S. Patent No. 5,656,272 to Le et al. (“Le”) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1038 - Y. Zhuang, et al., Golimumab Pharmacokinetics | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1039 - New Phase 3 Data Show Simponi Aria® (Golimumab) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1040 - New Phase 3 Data Show SIMPONI ARIA ® (golimumab) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1041 - A. Kavanaugh, et al., Golimumab, a New Human Tumor Necrosis(2009) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1042 - A. Kavanaugh, et al., Golimumab in Psoriatic Arthritis (2012) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1043 - A. Kavanaugh, et al., Patient-Reported Outcomes (2013) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1044 - A. Kavanaugh, et al., Clinical efficacy, radiographic (2014) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1050 - Appendix 6 Summary, CADTH (July 2015) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1051 - Industry Guidance (May 1998) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1006 - Dr. Roy M. Fleischmann curriculum vitae | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1052 - National Library of Medicine (2000) | Mar 20, 2026 | EXHIBIT | PETITIONER |
EX1005 - Declaration of Dr. Roy M. Fleischmann in Support of IPR Petition | Mar 20, 2026 | EXHIBIT | PETITIONER |
Inter Partes Review Petition of U.S. Patent 12,122,824 | Mar 20, 2026 | PAPER | PETITIONER |
Power of Attorney Accord BioPharma, Inc. | Mar 20, 2026 | PAPER | PETITIONER |
Power of Attorney of Bio-Thera Solutions, Ltd. | Mar 20, 2026 | PAPER | PETITIONER |
Power of Attorney of Intas Pharmaceuticals, Ltd. | Mar 20, 2026 | PAPER | PETITIONER |
Notice of Sotera Stipulation | Mar 20, 2026 | PAPER | PETITIONER |